DRG Market Assessment reports

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…

Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patients…

The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two…

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…

Parkinson’s disease (PD) is predominantly recognized as a motor disorder, but PD is also associated with a diverse mix of disabling nonmotor symptoms, including cognitive impairment and dementia…

As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that…

The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 with more on the horizon (e.g., ND-0612, AP-…

Parkinson’s disease (PD) treatment is complex. The disease is heterogeneous, requiring individualized treatment and frequent adjustments to achieve symptom control. New therapies that address PD…

Marketed therapies are often sufficient in early stages of Parkinson’s disease (PD), but as the disease progresses, they impose a considerable pill burden, progressively lose efficacy, and are…

Parkinson’s disease (PD) is the second-most common neurodegenerative disorder that, according to DRG epidemiology, afflicts more than 1.5 million people in the EU5. Although PD treatment has been…

The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade has launched with more on the horizon (e.g., ND-0612, AP-CD/…

Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill…